Formocortal
Chemical compound
- S01BA12 (WHO)
- 2-[(1S,2S,4R,8S,9S,11S,12R,13S)-16-(2-chloroethoxy)-12-fluoro-19-formyl-11-hydroxy-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-16,18-dien-8-yl]-2-oxoethyl acetate
- 2825-60-7
Y
- 17794
- DB13664 Y
- 254985
N
- 8E21R0Z4M5
- D04244
- Interactive image
- CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3CC(=C5[C@@]4(CCC(=C5)OCCCl)C)C=O)F)O)C)OC(O2)(C)C
InChI
- InChI=1S/C29H38ClFO8/c1-16(33)37-15-23(35)29-24(38-25(2,3)39-29)12-20-21-10-17(14-32)19-11-18(36-9-8-30)6-7-26(19,4)28(21,31)22(34)13-27(20,29)5/h11,14,20-22,24,34H,6-10,12-13,15H2,1-5H3/t20-,21-,22-,24+,26-,27-,28-,29+/m0/s1N
- Key:QNXUUBBKHBYRFW-QWAPGEGQSA-NN
N
Y (what is this?) (verify)Formocortal (INN), also known as fluoroformylone, is a corticosteroid used in dermatology[1] and ophthalmology.[2]
It was introduced in around 1970[1] and is not known to be marketed as of 2021[update].
See also
- Glucocorticoid
References
- ^ a b Aliperta G, Lattaro R (November 1971). "[On the topical use of a new steroid, formocortal, in the treatment of phlebodermitis and in cutaneous auto- and homo-grafts]". Minerva Cardioangiologica. 19 (11): 620–624. PMID 4942789.
- ^ Marchese A, Bozzolasco M, Gualco L, Schito GC, Debbia EA (2001). "Evaluation of spontaneous contamination of ocular medications". Chemotherapy. 47 (4): 304–308. doi:10.1159/000048538. PMID 11399868. S2CID 33870589.
- v
- t
- e
- Antagonists: Aglepristone
- Ketoconazole
- Mifepristone
- Ulipristal acetate
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
- See also
- Glucocorticoid receptor modulators
- Mineralocorticoids and antimineralocorticoids
- List of corticosteroids
 | This dermatologic drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
